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Abstract
Background: UbcH10 participates in proper metaphase to anaphase transition, and abrogation of
UbcH10 results in the premature separation of sister chromatids. To assess the potential role of
UbcH10 in colon cancer progression, we analyzed the clinicopathological relevance of UbcH10 in
colon cancer.
Methods: We firstly screened the expression profile of UbcH10 in various types of cancer tissues
as well as cell lines. Thereafter, using the colon cancer cells line, we manipulated the expression of
UbcH10 and evaluated the cell cycle profile and cellular proliferations. Furthermore, the
clinicopathological significance of UbcH10 was immunohistologically evaluated in patients with
colon cancer. Statistical analysis was performed using the student's t-test and Chi-square test.
Results: Using the colon cancer cells, depletion of UbcH10 resulted in suppression of cellular
growth whereas overexpression of UbcH10 promoted the cellular growth and oncogenic cellular
growth. Mitotic population was markedly alternated by the manipulation of UbcH10 expression.
Immunohistochemical analysis indicated that UbcH10 was significantly higher in colon cancer tissue
compared with normal colon epithelia. Furthermore, the clinicopathological evaluation revealed
that UbcH10 was associated with high-grade histological tumors.
Conclusion: The results show the clinicopathological significance of UbcH10 in the progression
of colon cancer. Thus UbcH10 may act as a novel biomarker in patients with colon cancer.
Background
Proper cell cycle progression is orchestrated by the control-
led oscillation of a series of cell cycle events. Deregulation
of appropriate cell cycle control often results in chromo-
somal instability, which is a potential trigger for the initia-
tion of cancer [1]. Dozens of molecules are expressed and
degraded in specific phases of the cell cycle through the
ubiquitin/proteasome pathway, and the ubiquitin/proteas-
ome system has been linked to the orchestration of several
important cell cycle events, such as proteolysis of cyclin-
dependent kinase and their inhibitors [2-4]. In this system,
substrate molecules are regulated for degradation by ubiq-
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uitin activating enzyme (E1), ubiquitin conjugating
enzyme (E2), and E3 ligase. Of these, two major E3 ligases
control a critical cell cycle stage. APC (anaphase-promoting
complex) mainly plays a role in the transition from mitosis
to G1, whereas the SCF (Skp1-cullin-F box) complex plays
a critical role from G1 to S [5,6]. During the transition from
mitosis to G1, APC activity is mainly regulated by the coac-
tivators Cdc20 and Cdh1. As cells enter mitosis, Cdc2
kinase enhances the formation of active Cdc20/APC com-
plex, which induces securin degradation. This, in turn,
induces the separation of sister chromatids through the
activation of separase. In late mitosis, Cdc20 is degraded by
Cdh1/APC and leads to the complete replacement of
Cdc20/APC by Cdh1/APC [7,8]. Recent studies demon-
strated that UbcH10 supplementation promotes dissocia-
tion of the spindle assembly checkpoint proteins Mad2 and
BubR1 from Cdc20, and then activates Cdc20/APC, which
leads to cyclin A and securin degradation [9,10]. These
results suggest that UbcH10 is potentially involved in the
termination of the spindle assembly checkpoint and fur-
ther implies that aberrant UbcH10 expression impairs the
spindle assembly checkpoint resulting in chromosomal
instability [11,12].
Previous epigenetic studies using a wide variety of cancers
have demonstrated that molecules that are associated
with the spindle assembly checkpoint aberrantly express
in certain malignancies [13-15]. Indeed, dysfunction of
several components of the spindle assembly checkpoint
including Mad1, Mad2, BubR1, and Aurora A are corre-
lated with chromosomal instability in malignant tumors
[13-15]. Moreover, some of these molecules are involved
in determining the efficacy of specific chemotherapeutic
agents [16,17]. Therefore, an investigation of spindle
checkpoint molecules will enhance our molecular back-
ground knowledge and lead us towards a potential treat-
ment for cancers.
Previous work with a cell line-based assay has demon-
strated UbcH10 involvement in chromosomal instability
[18-20]. To further validate the connection between
UbcH10 status and colon cancer progression, we devel-
oped a cell-line based assay and tissue array analyses to
elucidate the clinicopathological relevance of UbcH10 in
colon cancer. The results confirmed that aberrant UbcH10
expression promotes tumor formation by deregulating the
normal progression of the cell cycle. Thus, these results
provide evidence for the involvement of the spindle
assembly checkpoint in cancer and may possibly encour-
age the exploration of the cell cycle checkpoint machinery
associated with clinical oncology.
Methods
Plasmid preparation and small interfering RNA
The preparation of pcDNA3-Flag and pcDNA3-Flag-
UbcH10 plasmids have been previously reported [18].
Knockdown using small interfering RNA (siRNA) for
UbcH10 was carried out using the following target
sequence: (UbcH10 495- 5'-AACCTGCAAGAAAC-
CTACTCA-3') [19]. Transfection was conducted using
Lipofectamine2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer's protocol. Thereafter, cells were cul-
tured McCoy's medium (GIBCO, Carlsbad, CA) supple-
mented with 10% FBS and 1% penicillin/streptomycin
solution (GIBCO, Carlsbad, CA) for 10–14 days in the
presence of 500 μg/ml of G418 (Promega, Madison, WI)
and positive clones were selected in the presence of G418
(Promega, Madison, WI).
Antibodies and reagents
Antibodies against UbcH10 were purchased from Boston
Biochem (Cambridge, MA), and tubulin was purchased
from Calbiochem (Gibbstown, NJ). Western blot analysis
was performed using the ECL detection kit (Amersham,
Buckinghamshire, UK).
Cell cycle analysis
Cell cycle analysis was carried out by propidium iodide
(Sigma-Aldrich, St. Louis, MO) staining and fluorescent
activated cell sorting (FACS) analysis. Flow cytometric
analysis of the stained cells was performed using a FACS-
can (Becton Dickinson, Mountain View, CA).
Colony formation by soft agar assay
After transfection, viable cells were counted (2.0 × 105/
mL) and seeded onto soft agar [21] with slight modifica-
tion (Dr. Erik Flemington, Tulane Cancer Center, New
Orleans, LA). Briefly, a 1% agarose solution was prepared
with sterile water, the agarose was pipetted into each well
to make a thin film, and the cells were plated. Seven days
after seeding, colony formation was assessed by examina-
tion and counting under a microscope. Because the aggre-
gates of the untreated cells did not grow during the
experimental period, they were not considered colonies.
Each experiment was repeated at least thrice and the val-
ues are given as the results of mean (± S.D) value score.
Immunofluorescence
Immunofluorescence analysis was performed using the
phosphorylated histone H3 (Cell Signaling, Boston, MA)
as the primary antibody and fluorescein isothiocyanate
(FITC) as the secondary antibody (Jackson ImmunoRe-
search, West Grove, PA). The experiment was repeated at
least three times.
Immunohistochemical staining and prognostic analysis
Samples were deparaffinized, rehydrated, and the antigen
was retrieved in citrate buffer. Then the sections were
treated with hydrogen peroxide. Samples were incubated
using the UbcH10 antibody followed by the secondary
antibody (Vector Laboratories, Burlingame, CA), and
were then incubated with avidin-biotin peroxidase com-BMC Cancer 2009, 9:87 http://www.biomedcentral.com/1471-2407/9/87
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plex solution (DAKO Cytomation, Carpinteria, CA) and
3-amino-9-ethylcarbazole solution (DAKO Cytomation,
Carpinteria, CA). Tissue arrays were purchased from US
Biomax. (Rockville, MD). All patients provided the writ-
ten informed consent before analyze the surgically
removed materials. The expression of each molecule was
tested in cancer and normal-matched adjacent tissues. The
specificity and optimal concentration of the antibody was
verified using the test tissue array slide.
Scoring of immunohistochemical staining
Staining intensity and subcellular localization were evalu-
ated twice in a blinded manner based on a pre-agreed
staining scoring standard obtained from an expert pathol-
ogist (Dr. Cheng, Department of Pathology, University of
Pittsburgh). Staining intensity was scored using the fol-
lowing criteria: (a) 0–1, negative or low staining intensity
in >50% of the tumor cells or moderate to high in <50%
of the cells (low) and (b) 2–3, moderate to high staining
intensity in >50% of tumor cells [22].
Statistical analysis
Each value represents at least three independent experi-
ments. Statistical significance was evaluated with the two-
tailed Student's t-test and the Chi-square test. Fisher's
exact test was used for the analysis of the immunostaining
results and the clinicopathological data. p < 0.05 was con-
sidered statistically significant. All data were analyzed
with SPSS 14.0 (Chicago, IL) for Windows.
Results
Higher levels of UbcH10 in human cancer
It has been demonstrated that appropriate mitotic regula-
tion is essential for the proper progression of the cell cycle;
else abrogation of mitotic machinery might result in tetra-
ploidy or aneuploidy [8,9]. UbcH10 is thought as an
oncogenic potential enhancing carcinogenesis, according
to several large genome wide studies as well as cell line
based biophysical analysis. Previous biochemical studies
have demonstrated that UbcH10 plays a pivotal role in
orchestrating the metaphase to anaphase transition via
ubiquitin-proteosome pathway [10,20,23], supporting
the results of prior epigenetic studies. We analyzed
UbcH10 expression in various types of cancers to further
validate the oncogenic potential of UbcH10 in malignant
tumors status. Using a tissue array, we scored the staining
intensity of more than 500 tissue samples that had 16
types of cancer together with non-malignant tissues.
UbcH10 was highly expressed in several cancer types com-
pared with the adjacent non-malignant area (Fig. 1A).
Staining was significantly more intense between breast,
colon, lung, ovary, and cervical cancer tissues than in non-
malignant tissue (Fig. 1B, C), and UbcH10 was most pre-
dominantly seen in the nucleus but could also be found
in the cytoplasm of colon cancer cells (Fig. 1D). There was
no significant difference in UbcH10 cellular localization
between colon cancer and normal colon epithelial tissues
(data was not shown). Taken together, based on immono-
histochemical analysis, these results imply that impair-
ment of cell cycle regulation by aberrant UbcH10 may be
related with colon cancer.
Overexpression of UbcH10 enhances cellular proliferation 
in colon cancer cells
To analyze the role of UbcH10 in promoting cellular
growth associated with cell cycle progression through
mitosis, we overexpressed UbcH10 in colon cancer cells
(Fig. 2A). As shown in Fig. 2B, UbcH10 overexpression in
DLD1 cells resulted in a significant acceleration of cellular
growth. There are remarkable changes of doubling times
by the overexpression of UbcH10. Calculated doubling
times of DLD1 cells; 37.0 hrs (control cells), 21.5 hrs
(UbcH10-overexpressed cells), respectively. To test the
effect of UbcH10 on cell growth and oncogenic colony
formation, we conducted an anchorage-independent
growth assay and further measured the cell cycle profile in
DLD1 cells. UbcH10 overexpression promoted an
increase in the number and size (data not shown) of col-
onies on soft agar (Fig. 2C). Recent studies have demon-
strated that UbcH10 promotes the metaphase to anaphase
transition. To validate the role of UbcH10 in cell cycle reg-
ulation, we examined the cell cycle profile in UbcH10
overexpressed colon cancer cells. UbcH10 overexpression
in DLD1 cells reduced the G2/M-cell fraction (Fig. 2D). To
determine whether a decrease in the G2/M fraction was
dependant on the G2 or M phase, we analyzed the mitotic
population with immunofluorescence using phosphor-
ylated-histone H3. As shown in Fig. 2E, the percentage of
mitotic cells was markedly reduced in UbcH10-abundant
DLD1 cells compared with control cells. These results sug-
gest that increases of UbcH10 protein levels could lead to
aberrant cell cycle progression, particularly during mito-
sis, which, in turn, could promote oncogenesis in colon
cancer cells.
UbcH10 depletion suppresses colon cancer cell 
proliferation
We conducted UbcH10 depletion studies in colon cancer
cells (Fig. 3A) and examined the effects on cellular prolif-
eration as well as colony formation. As shown in Fig. 3B,
UbcH10 knockdown largely reduced cellular proliferation
in DLD1 cells. There are remarkable changes of doubling
times by the depletion of UbcH10. Calculated doubling
times of DLD1 cells; 37.0 hrs (control cells), and 53.7 hrs
(UbcH10-depleted cells), respectively. Control DLD1
cells showed a high capacity for colony formation in soft
agar, whereas both cell number and colony size decreased
significantly when UbcH10 was depleted. This result con-
firms a potential oncogenic effect of UbcH10 in colon
cancer cells (Fig. 3C). The G2/M cell fraction was signifi-BMC Cancer 2009, 9:87 http://www.biomedcentral.com/1471-2407/9/87
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Aberrant expression of UbcH10 in cancer Figure 1
Aberrant expression of UbcH10 in cancer. (A) Immunohistochemical analysis of the UbcH10-expression profile in vari-
ous types of cancer including 16 different organs revealed that UbcH10 is highly expressed in cancer compared with its adja-
cent non-malignant tissues of the colon, breast, lung, ovary, thymus, and uterine cervix. (B) Summary of the UbcH10-
expression profile in human tissues. Statistically significant differences were observed in the UbcH10 level between cancer and 
normal adjacent tissues. (C) Representative picture of the immunohistochemical analysis using normal colon epithelia and 
colon cancer tissue. UbcH10 is markedly expressed in colon cancer compared with normal colon epithelia. (D) Results of the 
immunostaining with UbcH10 in colon cancer. Higher levels of UbcH10 appeared in cancer, and it was mainly localized to the 
nucleus.
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Overexpression of UbcH10 promotes the cellular proliferation and alters the cell cycle profile in colon cancer Figure 2
Overexpression of UbcH10 promotes the cellular proliferation and alters the cell cycle profile in colon cancer. 
(A) UbcH10 overexpression in DLD1 colon cancer cells. (B) Cellular proliferation was markedly increased in UbcH10-overex-
pressed DLD1 cells compared with control cells. (C) Results of anchorage-independent colony formation soft-agar assay. The 
number of colonies was markedly increased in stably-transfected UbcH10 DLD1 colon cancer cells. (D) Cell cycle profile of 
overexpresed UbcH10 and control DLD1 cells shows that the population of G2/M cells is moderately decreased with the 
delivery of UbcH10. (E) a. Immunofluorescence with phosphorylated-histone H3 (pH3). The population of pH3 positive cells 
was decreased in UbcH10-overexpressed DLD1 cells. b. Quantification of immunofluorescence analysis (triplicate experi-
ments).
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Depletion of UbcH10 suppresses cellular proliferation in breast cancer cells Figure 3
Depletion of UbcH10 suppresses cellular proliferation in breast cancer cells. (A) UbcH10 knockdown in DLD1 
colon cancer cells. (B) The cellular proliferation rate was decreased in DLD1 cells by targeting siRNA for UbcH10. (C) Results 
of the anchorage independent colony formation assay using soft agar. The number of colonies was markedly decreased in 
DLD1 colon cancer cells by the delivery of UbcH10-siRNA. (D) Cell cycle patterns of UbcH10-knockdown and control DLD1 
cells revealed that populations of G2/M cells increase with UbcH10depletion. (E) a. Results of the immunocytochemical analysis 
using phosphorylated-histone H3 in DLD1 cells. UbcH10 knockdown increased the population of pH3 positive cells. b. Quanti-
fication of mitotic cells (triplicate experiments).
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cantly elevated in UbcH10-depleted DLD1 cells (Fig. 3D).
Consistent with the results of the above experiment, there
were an increased number of cells positive for phosphor-
ylated-histone H3 in the absence of UbcH10 (Fig. 3E).
These results further suggest that UbcH10 promotes onco-
genic proliferation and accelerates tumor growth, possibly
through mitotic progression.
Clinicopathological relevance of UbcH10 in patients with 
colon cancer
A potential function of UbcH10 in promoting progression
of colon cancer via regulation of mitotic checkpoint can
be revealed from the previous experiment. To correlate
our in vitro results to clinical or pathological relevance, we
evaluated the clinicopathological significance of UbcH10
in patients with colon cancer. In this study, we used an
independent set of 150 colon-neoplasm samples that
included four different types of normal colon epithelium
as controls. We analyzed the patient age, gender, tumor
size, lymph node status (N0-2), histological grade (G1-3),
and histological type of tumor and evaluated the clinico-
pathological relevance of UbcH10 in these patients.
Among the 150 patients, 69 patients (46.0%) were histo-
logically positive for UbcH10 and none of the controls
were UbcH10 positive. This result is consistent with our
previous observation (Fig. 1). There were no significant
differences between UbcH10 positive and negative can-
cers with respect to patient age (p = 0.674), gender (p =
0.779), tumor size (p = 0.601), lymph node metastasis (p
= 0.587), or histological type of cancer (p = 0.174) (Table
1). However, UbcH10 positive cancer was more fre-
quently and significantly categorized as a high-grade his-
tological tumor [Grade 3; UbcH10 (-): 2.98%, UbcH10
(+): 17.91%] (p < 0.001; Fig 4A–C). Results of this analy-
sis indicate that UbcH10 abundance is correlated with
high-grade histological tumors and suggests that higher
levels of UbcH10 could be associated with aggressive cel-
lular behavior and a potentially poor prognosis in
patients with colon cancer. Taken together, these results
show that UbcH10 has a substantial function in promot-
ing colon cancer progression and could be a potential
prognostic marker in patients with colon cancer.
Discussion
Appropriate cell cycle progression is orchestrated by a
series of molecular events in which the ubiquitin/proteas-
ome system is strongly associated with the cell cycle oscil-
lation machinery [1,2]. Therefore, dysfunction of this
system often leads to chromosomal instability and even-
tually results in the initiation of diseases, such as malig-
nant tumors [5,6]. The ubiquitin/proteasome system
includes ubiquitin activating enzyme (E1), ubiquitin con-
jugating enzyme (E2), and E3 ligase. Two major E3
ligases, SCF and APC, are critical for governing mitosis or
G1/S progression [5-7]. Loss of function of the SCF or APC
pathways is involved in the initiation or progression of
human cancer [24-26]. Previous work also provides evi-
dence that E2 proteins play an important role in regulat-
ing cell cycle progression. Indeed, recent studies
demonstrate that UbcH10 promotes the dissociation of
Mad2 from Cdc20, a crucial step in the metaphase to ana-
phase transition in which important molecules are
involved in the organization of appropriate spindle
assembly checkpoints [9,10]. The function of the spindle
assembly checkpoint is to ensure the proper separation of
duplicated daughter genomes during mitosis, and the dys-
function of this system often results in aneuploidy or
tetraploidy [25,26]. In fact, abnormal levels of Mad1,
Mad2, BubR1, and aurora A are observed in prostate,
stomach, and lung cancers [13-15,27]. Our results using
cultured cells, as well as the epigenetic analysis, further
confirms that dysfunction of the spindle assembly check-
point could potentially induce the initiation or progres-
sion of cancer.
Abnormal levels of UbcH10 promote aberrant cell cycle
progression and are potentially associated with tumor
progression [18-20,27]. Cell culture studies have indi-
cated the potential oncogenic role of UbcH10 [18,27].
Given the correlation between mitotic machinery dys-
function and chromosomal instability, the association
between UbcH10 and mitotic regulation further impli-
cates the involvement of UbcH10 in tumorigenesis
[18,20,27]. Our results suggest that abnormal levels of
UbcH10 increase oncogenic potential and accelerate cel-
lular proliferation. Furthermore, UbcH10 overexpression
or knockdown induced significant changes in the cell
cycle profile and the properties of oncogenic growth in
colon cancer cells, which is consistent with the prior
observation that UbcH10 participates in the progression
of cancer.
Clinicopathological analysis confirms the oncogenic role of 
UbcH10
The results of our examination of the association between
UbcH10, lymph-node metastasis, and histological grade
of colon cancers provoked the hypothesis that UbcH10
could promote tumor growth via abrogation of the spin-
dle assembly checkpoint [18,27]. Our analysis indicated
that UbcH10-negative colon cancers were associated with
a low histological grade and the loss of aggressive cancer
behavior. Thus, this potentially links UbcH10 activity to
the biological characteristics of tumor. Indeed, previous
results of large-scale genetic screening studies have
revealed that UbcH10 is one of the candidate molecules
related to aggressive behavior of the tumors [28-33].
Therefore, our clinicopathological assessment of UbcH10
is compatible with prior epigenetic and biological studies
that have implicated UbcH10 as a predictor of the biolog-
ical characteristics of cancer. Furthermore, lower levels ofBMC Cancer 2009, 9:87 http://www.biomedcentral.com/1471-2407/9/87
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The clinicopathological significance of UbcH10 in patients with colon cancer Figure 4
The clinicopathological significance of UbcH10 in patients with colon cancer. (A) Representative picture of nega-
tively or positively stained colon tissue samples. (B) Representative picture of breast cancer tissues immunohistochemically 
tested for UbcH10. UbcH10 was more abundantly expressed in grade 3 tumors compared with grade 1 tumors. There was no 
remarkable difference in UbcH10 cellular localization with regard to histological grade, whereas UbcH10 was relatively highly 
detected in the nucleus. (C) Summary of the level of UbcH10 and histological grade (G1-3) in patients with colon cancer.
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p31comet, another molecule that induces the metaphase
to anaphase transition, also acts as a potential prognostic
marker in cancer [34,35]. Moreover, Usp44 inhibits
Cdc20 degradation and counteracts UbcH10 to decelerate
the metaphase to anaphase transition [36]. Therefore, a
balance between UbcH10 and Usp44 could determine the
appropriate timing of sister chromatid separation and fur-
ther explain the significance of UbcH10 in cancer [36].
Our study had limitation. We could not adequately
address the phenomenon that overexpression of UbcH10
induced cellular proliferation while contradictory
decreased the population of mitosis. However, our results
were consistent with the results of previous literatures,
which may even be considered as strength of the present
study. Currently, role of UbcH10 is suggested to be only at
the end of G1-phase, being inconsistent with both in the
spindle checkpoint and inactivation of the APC/C [37].
Their suggestion would be the potential clue to explain
the contradictory phenomenon, and further investigation
is required to unveil the controversial point of UbcH10.
Conclusion
Dysfunction of the ubiquitin/proteasome system has
been strongly linked to carcinogenesis through its disrup-
tion of the balance between oncoproteins and tumor sup-
pressor proteins. Disruption of mitotic regulation at key
sites during the cell cycle can lead to genomic instability
and uncontrolled growth. The spindle assembly check-
point is a critical point that dictates chromatids separation
as well as the orchestration of appropriate cellular prolif-
eration. Our analyses verified the importance of the ubiq-
uitylation regulatory cascade in which one E2 protein
participates in the determination of mitotic progression.
The UbcH10-expression pattern in cancer supports the
notion that this regulatory axis controls cellular prolifera-
tion and that its abrogation leads to carcinogenesis. These
results provide a further understanding of UbcH10 and its
role in cell cycle regulation and colon cancer formation.
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